Kura Oncology, Inc. (KURA) has a consensus analyst rating of Buy, based on 16 analysts covering the stock. Of those, 14 recommend buying, 2 recommend holding, and 0 recommend selling.
The analyst consensus price target for KURA is $28.20, representing a +208.5% upside from the current price of $9.14. Price targets range from a low of $15.00 to a high of $40.00.
